PCSA - Processa Pharmaceuticals, Inc.
2.8
0.260 9.286%
Share volume: 87,925
Last Updated: 03-04-2026
Pharmaceutical Products/Pharmaceutical Preparations:
3.72%
PREVIOUS CLOSE
CHG
CHG%
$2.54
0.26
0.10%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 06-30-2025 | 09-30-2025 | |
|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
| Report Date | 05-10-2024 | 08-13-2024 | 10-30-2024 | 03-20-2025 | 05-08-2025 | 08-07-2025 | 11-06-2025 | |
| Total revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| nan% | nan% | nan% | nan% | nan% | ||||
| Operating expenses | 2.810 M | 3.082 M | 3.425 M | 2.735 M | 2.847 M | 3.951 M | 3.489 M | |
| Selling general and admin | 1.271 M | 1.352 M | 1.137 M | 1.023 M | 1.258 M | 1.503 M | 1.827 M | |
| Research and development | 1.539 M | 1.730 M | 2.288 M | 1.712 M | 1.589 M | 2.447 M | 1.662 M | |
| Total expenses | 2.810 M | 3.082 M | 3.425 M | 2.735 M | 2.847 M | 3.951 M | 3.489 M | |
| 9.70% | 11.12% | -20.15% | 4.10% | 38.77% | -11.69% | |||
| Operating income | -2.810 M | -3.082 M | -3.425 M | -2.735 M | -2.847 M | -3.951 M | -3.489 M | |
| Ebit | -2.810 M | -3.010 M | -3.425 M | -2.735 M | -2.834 M | -3.951 M | -3.489 M | |
| Pretax income | -2.810 M | -3.010 M | -3.385 M | -2.645 M | -2.834 M | -3.951 M | -3.489 M | |
| 7.14% | 12.44% | -21.84% | 7.14% | 39.39% | -11.69% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income | -2.726 M | -3.010 M | -3.385 M | -2.729 M | -2.834 M | -3.934 M | -3.437 M | |
| -10.41% | -12.44% | 19.38% | -3.87% | -38.79% | 12.64% |